GlassScriptPhysician profile
Alakh Gulati
NPI 1407397656
$2,092.88
in general payments reported to CMS, 2019-2025
17 companies · $705 in 2025
The $705 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.52 · 2023: $93.24 · 2024: $1,272 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,070.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $731.25 | 2024 | Voquezna |
| Abbvie INC. | $485.31 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $173.76 | 2023-2025 | Entyvio, Eohilia |
| Olympus America INC. | $141.39 | 2024 | Endoclot Phs |
| Capsovision, INC. | $104.82 | 2025 | Capsocam Plus |
| Aimmune Therapeutics, INC. | $98.45 | 2024-2025 | Zenpep |
| Pfizer INC. | $72.14 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $44.64 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.65 | 2024-2025 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $39.37 | 2024 | Tremfya, Stelara |
| Nestle Healthcare Nutrition INC. | $30.91 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $28.02 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $22.52 | 2020 | |
| Ardelyx, INC. | $21.40 | 2025 | Ibsrela |
| Gilead Sciences, INC. | $20.95 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eagle Pharmaceuticals, INC. | $19.28 | 2024 | |
| Celltrion USA INC. | $17.02 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alakh Gulati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.